2000, ISBN 0198205430, 440
Although often viewed as ineffectual intellectuals, or a spent political force, Left Liberals had become the third largest party in German politics by 1914 and...
History | Germany Politics and government | Liberalism | modern history (1700 to 1945) | 20th century
History | Germany Politics and government | Liberalism | modern history (1700 to 1945) | 20th century
eBook
2012, ISBN 9781459704336, 271
Book
European Journal of Surgical Oncology, ISSN 0748-7983, 2017, Volume 43, Issue 5, pp. S3 - S4
Journal Article
Pain, ISSN 0304-3959, 02/2014, Volume 155, Issue 2, pp. 232 - 243
Risk factors for chronic pain up to 9 months after breast cancer surgery include younger age, psychological vulnerability, axillary clearance surgery, and...
Chronic postsurgical pain | Postoperative pain | Breast cancer | Nerve division | Psychology | Surgery | RISK-FACTORS | VALIDATION | FOLLOW-UP | NEUROSCIENCES | CLINICAL NEUROLOGY | PERSISTENT POSTSURGICAL PAIN | NEUROPATHIC PAIN | INGUINAL-HERNIA REPAIR | INTERCOSTOBRACHIAL NERVE | DISPOSITIONAL OPTIMISM | ANESTHESIOLOGY | LYMPH-NODE BIOPSY | Breast Neoplasms - surgery | Predictive Value of Tests | Prospective Studies | Age Factors | Pain, Postoperative - psychology | Humans | Middle Aged | Treatment Outcome | Socioeconomic Factors | Pain Measurement - methods | Pain, Postoperative - diagnosis | Breast Neoplasms - psychology | Pain, Postoperative - epidemiology | Pain Measurement - psychology | Female | Aged | Population Surveillance - methods | Breast Neoplasms - epidemiology | Cohort Studies | Research | Analysis | Oncology, Experimental | Chronic pain | Cancer
Chronic postsurgical pain | Postoperative pain | Breast cancer | Nerve division | Psychology | Surgery | RISK-FACTORS | VALIDATION | FOLLOW-UP | NEUROSCIENCES | CLINICAL NEUROLOGY | PERSISTENT POSTSURGICAL PAIN | NEUROPATHIC PAIN | INGUINAL-HERNIA REPAIR | INTERCOSTOBRACHIAL NERVE | DISPOSITIONAL OPTIMISM | ANESTHESIOLOGY | LYMPH-NODE BIOPSY | Breast Neoplasms - surgery | Predictive Value of Tests | Prospective Studies | Age Factors | Pain, Postoperative - psychology | Humans | Middle Aged | Treatment Outcome | Socioeconomic Factors | Pain Measurement - methods | Pain, Postoperative - diagnosis | Breast Neoplasms - psychology | Pain, Postoperative - epidemiology | Pain Measurement - psychology | Female | Aged | Population Surveillance - methods | Breast Neoplasms - epidemiology | Cohort Studies | Research | Analysis | Oncology, Experimental | Chronic pain | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9917, pp. 603 - 613
Summary Background The TARGIT-A trial compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy (TARGIT) versus fractionated...
Internal Medicine | IRRADIATION | WOMEN | MEDICINE, GENERAL & INTERNAL | LUMPECTOMY PLUS TAMOXIFEN | CONSERVING SURGERY | ENERGY X-RAYS | CLINICAL-TRIALS | RECURRENCE | ADJUVANT RADIOTHERAPY | MULTICENTRICITY | RADIATION-THERAPY | Breast Neoplasms - surgery | Carcinoma, Ductal, Breast - surgery | Radiotherapy - mortality | Neoplasm Recurrence, Local - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Treatment Outcome | Neoplasm Recurrence, Local - mortality | Carcinoma, Ductal, Breast - mortality | Breast Neoplasms - radiotherapy | Intraoperative Care - mortality | Intraoperative Care - methods | Carcinoma, Ductal, Breast - radiotherapy | Radiotherapy - methods | Breast Neoplasms - mortality | Female | Aged | Mastectomy, Segmental - mortality | Mastectomy, Segmental - methods | Care and treatment | Usage | Patient outcomes | Breast cancer | Research | Radiotherapy | Comparative analysis | Radiation therapy | Cancer therapies | Surgery | Medical prognosis | Mortality
Internal Medicine | IRRADIATION | WOMEN | MEDICINE, GENERAL & INTERNAL | LUMPECTOMY PLUS TAMOXIFEN | CONSERVING SURGERY | ENERGY X-RAYS | CLINICAL-TRIALS | RECURRENCE | ADJUVANT RADIOTHERAPY | MULTICENTRICITY | RADIATION-THERAPY | Breast Neoplasms - surgery | Carcinoma, Ductal, Breast - surgery | Radiotherapy - mortality | Neoplasm Recurrence, Local - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Treatment Outcome | Neoplasm Recurrence, Local - mortality | Carcinoma, Ductal, Breast - mortality | Breast Neoplasms - radiotherapy | Intraoperative Care - mortality | Intraoperative Care - methods | Carcinoma, Ductal, Breast - radiotherapy | Radiotherapy - methods | Breast Neoplasms - mortality | Female | Aged | Mastectomy, Segmental - mortality | Mastectomy, Segmental - methods | Care and treatment | Usage | Patient outcomes | Breast cancer | Research | Radiotherapy | Comparative analysis | Radiation therapy | Cancer therapies | Surgery | Medical prognosis | Mortality
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2012, Volume 11, Issue 2, pp. 150 - 156
Summary Background More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of...
Neurology | CRITERIA | IMMUNE-RESPONSE | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | REPAIR | THERAPY | MODELS | DISEASE | DISABILITY | STROMAL CELLS | CLINICAL NEUROLOGY | TRANSPLANTATION | Severity of Illness Index | Multiple Sclerosis, Chronic Progressive - physiopathology | Humans | Middle Aged | Male | Treatment Outcome | Transplantation, Autologous - methods | Vision Disorders - drug therapy | Mesenchymal Stem Cell Transplantation - adverse effects | Feasibility Studies | Mesenchymal Stem Cell Transplantation - methods | Vision Disorders - diagnosis | Vision Disorders - physiopathology | Leukocytes, Mononuclear - transplantation | Transplantation, Autologous - adverse effects | Adult | Female | Infusions, Intravenous | Multiple Sclerosis, Chronic Progressive - drug therapy | Mesenchymal Stromal Cells - physiology | Multiple sclerosis | Care and treatment | Neurosciences | Analysis | Stem cells | Autografts | Neuroprotection | Animal models | Intravenous administration | Optic nerve | Mesenchyme | Exanthema | Visual evoked response | Visual pathways | Clinical trials | Retina | visual field | Acuity | Color vision | Structure-function relationships
Neurology | CRITERIA | IMMUNE-RESPONSE | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | REPAIR | THERAPY | MODELS | DISEASE | DISABILITY | STROMAL CELLS | CLINICAL NEUROLOGY | TRANSPLANTATION | Severity of Illness Index | Multiple Sclerosis, Chronic Progressive - physiopathology | Humans | Middle Aged | Male | Treatment Outcome | Transplantation, Autologous - methods | Vision Disorders - drug therapy | Mesenchymal Stem Cell Transplantation - adverse effects | Feasibility Studies | Mesenchymal Stem Cell Transplantation - methods | Vision Disorders - diagnosis | Vision Disorders - physiopathology | Leukocytes, Mononuclear - transplantation | Transplantation, Autologous - adverse effects | Adult | Female | Infusions, Intravenous | Multiple Sclerosis, Chronic Progressive - drug therapy | Mesenchymal Stromal Cells - physiology | Multiple sclerosis | Care and treatment | Neurosciences | Analysis | Stem cells | Autografts | Neuroprotection | Animal models | Intravenous administration | Optic nerve | Mesenchyme | Exanthema | Visual evoked response | Visual pathways | Clinical trials | Retina | visual field | Acuity | Color vision | Structure-function relationships
Journal Article
JNCI: Journal of the National Cancer Institute, ISSN 0027-8874, 04/2017, Volume 109, Issue 4
Journal Article
1973, 65
Book
American Journal of Obstetrics and Gynecology, ISSN 0002-9378, 2015, Volume 213, Issue 6, pp. 779 - 788
Cerebral palsy (CP) is heterogeneous with different clinical types, comorbidities, brain imaging patterns, causes, and now also heterogeneous underlying...
Obstetrics and Gynecology | genetic variants | DNA variants | epidemiological risk factors | causes | cerebral palsy | genomics | heterogeneity | whole exome sequencing | ASSOCIATIONS | FORM | TERM | FAMILY | BASE | OBSTETRICS & GYNECOLOGY | INTRAPARTUM RISK-FACTORS | INFANTS | MUTATION | ANTECEDENTS | NEWBORN ENCEPHALOPATHY | Pregnancy, Multiple | Premature Birth | Humans | Pregnancy Complications | Risk Factors | Fetal Growth Retardation | Placenta Diseases | Obstetric Labor Complications | False Positive Reactions | Hypoxia-Ischemia, Brain - complications | Genetic Variation | Pregnancy | Congenital Abnormalities | Defensive Medicine | Cardiotocography | Cerebral Palsy - etiology | Dystocia | Sex Factors | Female | Mutation | Nuchal Cord | Infant, Newborn | Infection - complications | Metabolism, Inborn Errors - complications | Cerebral palsy | Genetic disorders | Growth | Comorbidity | Mortality | Genomics | Birth defects | Gene expression | Costs (Law) | Genetic research | Fetus | Nucleotide sequencing | DNA sequencing
Obstetrics and Gynecology | genetic variants | DNA variants | epidemiological risk factors | causes | cerebral palsy | genomics | heterogeneity | whole exome sequencing | ASSOCIATIONS | FORM | TERM | FAMILY | BASE | OBSTETRICS & GYNECOLOGY | INTRAPARTUM RISK-FACTORS | INFANTS | MUTATION | ANTECEDENTS | NEWBORN ENCEPHALOPATHY | Pregnancy, Multiple | Premature Birth | Humans | Pregnancy Complications | Risk Factors | Fetal Growth Retardation | Placenta Diseases | Obstetric Labor Complications | False Positive Reactions | Hypoxia-Ischemia, Brain - complications | Genetic Variation | Pregnancy | Congenital Abnormalities | Defensive Medicine | Cardiotocography | Cerebral Palsy - etiology | Dystocia | Sex Factors | Female | Mutation | Nuchal Cord | Infant, Newborn | Infection - complications | Metabolism, Inborn Errors - complications | Cerebral palsy | Genetic disorders | Growth | Comorbidity | Mortality | Genomics | Birth defects | Gene expression | Costs (Law) | Genetic research | Fetus | Nucleotide sequencing | DNA sequencing
Journal Article
Journal of Clinical Immunology, ISSN 0271-9142, 1/2010, Volume 30, Issue 1, pp. 99 - 105
Treatment with alemtuzumab is highly effective in relapsing–remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab...
reconstitution | Medical Microbiology | T1 B cell: transitional type I B cell | Biomedicine | Immunology | autoimmunity | BAFF: B-cell activating factor | Internal Medicine | Infectious Diseases | B cells | Autoimmunity | Reconstitution | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | REGENERATION | SJOGRENS-SYNDROME | DEPLETION | ANTIBODY | PERIPHERAL-BLOOD | IMMUNOLOGY | OVEREXPRESSION | RECOVERY | APRIL | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Immunologic Memory - drug effects | Antibodies, Monoclonal, Humanized | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Adult | Female | B-Lymphocytes - pathology | T-Lymphocytes - pathology | B-Lymphocytes - metabolism | Multiple Sclerosis, Relapsing-Remitting - pathology | Cell Survival - drug effects | B-Cell Activating Factor - biosynthesis | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - blood | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Cells, Cultured | Immunophenotyping | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | B-Lymphocytes - drug effects | B-Lymphocytes - immunology | Antibodies, Monoclonal - administration & dosage | B-Cell Activating Factor - genetics | Cell Differentiation - drug effects | Adolescent | T-Lymphocytes - immunology | B-Cell Activating Factor - blood | Antibodies, Neoplasm - adverse effects | Multiple sclerosis | Memory (Computers) | Drug therapy | T cells
reconstitution | Medical Microbiology | T1 B cell: transitional type I B cell | Biomedicine | Immunology | autoimmunity | BAFF: B-cell activating factor | Internal Medicine | Infectious Diseases | B cells | Autoimmunity | Reconstitution | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | REGENERATION | SJOGRENS-SYNDROME | DEPLETION | ANTIBODY | PERIPHERAL-BLOOD | IMMUNOLOGY | OVEREXPRESSION | RECOVERY | APRIL | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Immunologic Memory - drug effects | Antibodies, Monoclonal, Humanized | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Adult | Female | B-Lymphocytes - pathology | T-Lymphocytes - pathology | B-Lymphocytes - metabolism | Multiple Sclerosis, Relapsing-Remitting - pathology | Cell Survival - drug effects | B-Cell Activating Factor - biosynthesis | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - blood | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Cells, Cultured | Immunophenotyping | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | B-Lymphocytes - drug effects | B-Lymphocytes - immunology | Antibodies, Monoclonal - administration & dosage | B-Cell Activating Factor - genetics | Cell Differentiation - drug effects | Adolescent | T-Lymphocytes - immunology | B-Cell Activating Factor - blood | Antibodies, Neoplasm - adverse effects | Multiple sclerosis | Memory (Computers) | Drug therapy | T cells
Journal Article
BMC Cancer, ISSN 1471-2407, 09/2009, Volume 9, Issue 1, pp. 307 - 307
Background: AMP-activated protein kinase (AMPK) acts as a cellular fuel gauge that responds to energy stress by suppressing cell growth and biosynthetic...
MAMMALIAN TARGET | METFORMIN | ACTIVATED PROTEIN-KINASE | ONCOLOGY | FATTY-ACID OXIDATION | MALONYL-COA | PHOSPHORYLATION | GLUCOSE | ACETYL-COA CARBOXYLASE | CELLULAR-ENERGY | LKB1 | Immunohistochemistry | AMP-Activated Protein Kinases - metabolism | Phosphorylation | Follow-Up Studies | Signal Transduction | Humans | Middle Aged | Breast Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Aged | Cohort Studies | Usage | Care and treatment | Physiological aspects | Development and progression | Breast cancer | Genetic aspects | Cellular signal transduction | Research | Protein kinases
MAMMALIAN TARGET | METFORMIN | ACTIVATED PROTEIN-KINASE | ONCOLOGY | FATTY-ACID OXIDATION | MALONYL-COA | PHOSPHORYLATION | GLUCOSE | ACETYL-COA CARBOXYLASE | CELLULAR-ENERGY | LKB1 | Immunohistochemistry | AMP-Activated Protein Kinases - metabolism | Phosphorylation | Follow-Up Studies | Signal Transduction | Humans | Middle Aged | Breast Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Aged | Cohort Studies | Usage | Care and treatment | Physiological aspects | Development and progression | Breast cancer | Genetic aspects | Cellular signal transduction | Research | Protein kinases
Journal Article
2017, Third edition., ISBN 5862700102, 3 volumes (loose-leaf)
Book
PLoS ONE, ISSN 1932-6203, 01/2012, Volume 7, Issue 1, p. e30334
Background: Respiratory tract infections (RTIs) are common in children and generally self-limiting, yet often result in consultations to primary care. Frequent...
PRESCHOOL-CHILDREN | EDUCATIONAL INTERVENTION | MULTIDISCIPLINARY SCIENCES | ACUTE OTITIS-MEDIA | PARENTS | GENERAL-PRACTICE | MASTOIDITIS | RANDOMIZED CONTROLLED-TRIAL | OUTCOMES | PRESCRIBING STRATEGIES | COMMUNICATION | Anti-Bacterial Agents - therapeutic use | Acute Disease | Respiratory Tract Infections - therapy | Humans | Adolescent | Child, Preschool | Infant | Respiratory Tract Infections - epidemiology | Referral and Consultation - utilization | Child | Infant, Newborn | Infection | Parenting | Medical research | Drug resistance in microorganisms | Antibiotics | Medicine, Experimental | Respiratory tract diseases | Health care | Caregivers | Parental behavior | Health sciences | Pediatrics | Parents | Ear diseases | Families & family life | Clinical trials | Infections | Research | Drug resistance | Data bases | Respiratory tract | Parents & parenting | Education | Children | Prescriptions | Rheumatic fever | Public health | Quantitative analysis | Patient admissions | Primary care | Medicine | Studies | Hospitals | Consulting | Antimicrobial resistance | Ambulatory care
PRESCHOOL-CHILDREN | EDUCATIONAL INTERVENTION | MULTIDISCIPLINARY SCIENCES | ACUTE OTITIS-MEDIA | PARENTS | GENERAL-PRACTICE | MASTOIDITIS | RANDOMIZED CONTROLLED-TRIAL | OUTCOMES | PRESCRIBING STRATEGIES | COMMUNICATION | Anti-Bacterial Agents - therapeutic use | Acute Disease | Respiratory Tract Infections - therapy | Humans | Adolescent | Child, Preschool | Infant | Respiratory Tract Infections - epidemiology | Referral and Consultation - utilization | Child | Infant, Newborn | Infection | Parenting | Medical research | Drug resistance in microorganisms | Antibiotics | Medicine, Experimental | Respiratory tract diseases | Health care | Caregivers | Parental behavior | Health sciences | Pediatrics | Parents | Ear diseases | Families & family life | Clinical trials | Infections | Research | Drug resistance | Data bases | Respiratory tract | Parents & parenting | Education | Children | Prescriptions | Rheumatic fever | Public health | Quantitative analysis | Patient admissions | Primary care | Medicine | Studies | Hospitals | Consulting | Antimicrobial resistance | Ambulatory care
Journal Article
Brain, ISSN 0006-8950, 08/2010, Volume 133, Issue 8, pp. 2232 - 2247
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade...
Multiple sclerosis | Protective autoimmunity | Neurotrophins | Immunotherapy | BRAIN-LESIONS | multiple sclerosis | NEUROTROPHIC FACTOR | INDUCED DEMYELINATION | CNS | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPEUTIC LYMPHOCYTE DEPLETION | ACTIVATED T-CELLS | immunotherapy | protective autoimmunity | CENTRAL-NERVOUS-SYSTEM | SPINAL-CORD-INJURY | neurotrophins | EXPRESSION | GROWTH-FACTOR-I | Antibodies, Neoplasm - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Interferon-beta - therapeutic use | Young Adult | Antibodies, Monoclonal, Humanized | Intercellular Signaling Peptides and Proteins - metabolism | Lymphocytes - immunology | Adult | Female | Retrospective Studies | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - immunology | Cross-Sectional Studies | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Cells, Cultured | Rats | Treatment Outcome | Alemtuzumab | Rats, Sprague-Dawley | Animals | Interferon beta-1a | Longitudinal Studies | Autoimmunity - drug effects | Neuroimmunomodulation - drug effects | Immunologic Factors - therapeutic use | Autoimmunity
Multiple sclerosis | Protective autoimmunity | Neurotrophins | Immunotherapy | BRAIN-LESIONS | multiple sclerosis | NEUROTROPHIC FACTOR | INDUCED DEMYELINATION | CNS | NEUROSCIENCES | CLINICAL NEUROLOGY | THERAPEUTIC LYMPHOCYTE DEPLETION | ACTIVATED T-CELLS | immunotherapy | protective autoimmunity | CENTRAL-NERVOUS-SYSTEM | SPINAL-CORD-INJURY | neurotrophins | EXPRESSION | GROWTH-FACTOR-I | Antibodies, Neoplasm - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Interferon-beta - therapeutic use | Young Adult | Antibodies, Monoclonal, Humanized | Intercellular Signaling Peptides and Proteins - metabolism | Lymphocytes - immunology | Adult | Female | Retrospective Studies | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - immunology | Cross-Sectional Studies | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Cells, Cultured | Rats | Treatment Outcome | Alemtuzumab | Rats, Sprague-Dawley | Animals | Interferon beta-1a | Longitudinal Studies | Autoimmunity - drug effects | Neuroimmunomodulation - drug effects | Immunologic Factors - therapeutic use | Autoimmunity
Journal Article